Device-Biotech Culture Clash: BIO Learns From Medtronic/Genzyme Deal
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's initial experience from its joint venture with Genzyme suggests that in teaming with a biotech company, the device firm must alter its view of acceptable risks and potential rewards